| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Harald Lapp | Q87662882 |
| P2093 | author name string | John C Burnett | |
| Guido Boerrigter | |||
| P2860 | cites work | Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q22306347 |
| ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...] | Q22306349 | ||
| An epigrammatic (abridged) recounting of the myriad tales of astonishing deeds and dire consequences pertaining to nitric oxide and reactive oxygen species in mitochondria with an ancillary missive concerning the origins of apoptosis | Q23912112 | ||
| NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 | ||
| Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials | Q28246006 | ||
| Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use | Q28263273 | ||
| Gene and precursor structures of human C-type natriuretic peptide | Q28274235 | ||
| Combination of isosorbide dinitrate and hydralazine in blacks with heart failure | Q28292266 | ||
| Gene Expression, Secretion, and Autocrine Action of C-Type Natriuretic Peptide in Cultured Adult Rat Cardiac Fibroblasts | Q28575103 | ||
| Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor | Q28582616 | ||
| Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling | Q29615163 | ||
| Protein S-nitrosylation: purview and parameters | Q29615181 | ||
| Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase | Q31805259 | ||
| Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. | Q31940132 | ||
| Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial | Q33916200 | ||
| Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance | Q34194262 | ||
| A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps) | Q34243440 | ||
| Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure | Q34405182 | ||
| Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels | Q35009484 | ||
| NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle | Q35044464 | ||
| Cardiac fibrosis in mice lacking brain natriuretic peptide | Q35677878 | ||
| Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes | Q35812341 | ||
| Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo. | Q36054367 | ||
| Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. | Q36295757 | ||
| Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. | Q36622456 | ||
| The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction | Q36713575 | ||
| cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology | Q36843654 | ||
| Acute decompensated heart failure and the cardiorenal syndrome | Q37044895 | ||
| Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure | Q37108093 | ||
| B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity | Q37217952 | ||
| Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide | Q39485842 | ||
| Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. | Q39750341 | ||
| Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. | Q40483773 | ||
| Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. | Q40569818 | ||
| Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation. | Q41604430 | ||
| A-350619: a novel activator of soluble guanylyl cyclase | Q42049434 | ||
| Effects of intravenously administered C-type natriuretic peptide in humans: comparison with atrial natriuretic peptide | Q42454978 | ||
| The tumultuous journey of nesiritide: past, present, and future | Q43123466 | ||
| Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure | Q43576511 | ||
| Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs | Q43640255 | ||
| Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study | Q43787674 | ||
| Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). | Q44108429 | ||
| Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits | Q44182297 | ||
| Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases | Q44248152 | ||
| Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure | Q44310085 | ||
| Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase | Q44445674 | ||
| Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase | Q44626758 | ||
| Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure | Q44801369 | ||
| Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure | Q44853867 | ||
| Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice | Q44935527 | ||
| Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine | Q45037057 | ||
| Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition | Q45069627 | ||
| Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy | Q45235067 | ||
| Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study | Q45337067 | ||
| Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. | Q46035107 | ||
| Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure | Q46630199 | ||
| Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form | Q46778176 | ||
| Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase | Q46839590 | ||
| Long-term use of sildenafil in the therapeutic management of heart failure | Q46883859 | ||
| Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials | Q46928598 | ||
| Bioactivity and metabolism of C-type natriuretic peptide in normal man | Q48108551 | ||
| Renal actions of synthetic dendroaspis natriuretic peptide | Q48146580 | ||
| Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet | Q48178091 | ||
| Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure | Q48260348 | ||
| Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial | Q48276995 | ||
| Different effects of atrial and C-type natriuretic peptide on the urinary excretion of endothelin-1 in man. | Q48365608 | ||
| Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. | Q48386405 | ||
| BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. | Q48417679 | ||
| Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. | Q48564630 | ||
| Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. | Q48643573 | ||
| Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. | Q48649829 | ||
| Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. | Q52923660 | ||
| Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. | Q53178301 | ||
| Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. | Q53353952 | ||
| Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. | Q53499842 | ||
| Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. | Q53560448 | ||
| Subcutaneous administration of brain natriuretic peptide in experimental heart failure. | Q54029914 | ||
| Cardiovascular and renal actions of C-type natriuretic peptide | Q54277308 | ||
| Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure | Q57396392 | ||
| Haemodynamic and clinical effects of ularitide in decompensated heart failure | Q66829320 | ||
| Action of C-type natriuretic peptide in isolated canine arteries and veins | Q70555577 | ||
| Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure | Q71769824 | ||
| C-type natriuretic peptide: a selective cardiovascular peptide | Q72955879 | ||
| Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs | Q73377155 | ||
| Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine | Q77700106 | ||
| Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations | Q79691736 | ||
| Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? | Q79837496 | ||
| Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism | Q80063618 | ||
| Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart | Q80107937 | ||
| Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor | Q80255770 | ||
| Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure | Q80725402 | ||
| C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction | Q81397064 | ||
| Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy | Q81441501 | ||
| P433 | issue | 191 | |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 485-506 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Handbook of experimental pharmacology | Q26841924 |
| P1476 | title | Modulation of cGMP in heart failure: a new therapeutic paradigm |
| Q34141284 | A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response |
| Q35994136 | Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction |
| Q38155422 | Changes in renal function in congestive heart failure |
| Q47918870 | Cocaine self-administration by rats is inhibited by cyclic GMP-elevating agents: involvement of epigenetic markers |
| Q87098224 | Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium |
| Q38061473 | Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option? |
| Q38862807 | Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation |
| Q42512380 | Natriuretic peptides regulate heart rate and sinoatrial node function by activating multiple natriuretic peptide receptors |
| Q39024203 | Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure |
| Q35879351 | Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines |
| Q37537154 | Role of guanylate cyclase modulators in decompensated heart failure |
| Q36609843 | Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network |
| Q37327400 | SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium |
| Q38000562 | Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. |
| Q27661554 | Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase |
| Q27024279 | The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction |
| Q37416187 | The role of exercise on L-arginine nitric oxide pathway in chronic heart failure |
| Q57152438 | Upregulation of Myocardial and Vascular Phosphodiesterase 9A in A Model of Atherosclerotic Cardiovascular Disease |
Search more.